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BACKGROUND: Drug resistance is a major problem in ovarian cancer. Triggering apoptosis using death ligands such as tumour necrosis
factor-related apoptosis inducing ligand (TRAIL) might overcome chemoresistance.
METHODS: We investigated whether acquired cisplatin resistance affects sensitivity to recombinant human (rh) TRAIL alone or in
combination with cisplatin in an ovarian cancer cell line model consisting of A2780 and its cisplatin-resistant subline CP70.
RESULTS: Combining cisplatin and rhTRAIL strongly enhanced apoptosis in both cell lines. CP70 expressed less caspase 8 protein,
whereas mRNA levels were similar compared with A2780. Pre-exposure of particularly CP70 to cisplatin resulted in strongly elevated
caspase 8 protein and mRNA levels. Caspase 8 mRNA turnover and protein stability in the presence or absence of cisplatin did not
differ between both cell lines. Cisplatin-induced caspase 8 protein levels were essential for the rhTRAIL-sensitising effect as
demonstrated using caspase 8 small-interfering RNA (siRNA) and caspase-8 overexpressing constructs. Cellular FLICE-inhibitory
protein (c-FLIP) and p53 siRNA experiments showed that neither an altered caspase 8/c-FLIP ratio nor a p53-dependent increase in
DR5 membrane expression following cisplatin were involved in rhTRAIL sensitisation.
CONCLUSION: Cisplatin enhances rhTRAIL-induced apoptosis in cisplatin-resistant ovarian cancer cells, and induction of caspase 8
protein expression is the key factor of rhTRAIL sensitisation.
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In ovarian cancer, the majority of tumours acquire drug resistance.
Response rates to first-line platinum-based therapy are more than
80%, but most patients with advanced disease will finally relapse
and die because of acquired drug resistance (Agarwal and Kaye,
2003). Chemoresistance is attributed to numerous mechanisms,
which can be broadly divided into decreased DNA damage
response via p53 and increased cell survival, mainly through
defects in apoptosis (Wernyj and Morin, 2004). A meta-analysis
showed that aberrant p53 status results in a worse 5-year survival
for ovarian cancer patients (Crijns et al, 2003). Triggering
apoptosis directly via the extrinsic apoptotic pathway might
circumvent escape mechanisms developed by cancer cells.
Especially the recombinant human (rh) form of the death ligand
tumour necrosis factor-related apoptosis inducing ligand (TRAIL)
is considered to be interesting for clinical use because of its ability
to induce apoptosis in several types of cancer cell lines and
xenografts (Wiley et al, 1995; Pitti et al, 1996; Ashkenazi et al,
2008). Preliminary data from a phase I trial with rhTRAIL showed
no major toxicity (Herbst et al, 2010). TRAIL induces apoptosis by
binding to death receptor 4 (DR4) and DR5 (Ashkenazi et al,
2008). Binding to these DRs causes receptor trimerisation and
recruitment of the adaptor protein Fas-associated death domain
(FADD). This in turn recruits caspase 8, resulting in the formation
of the death-inducing signalling complex (DISC) (Peter, 2000).
Binding of caspase 8 to the DISC causes its activation (Boatright
et al, 2003), with subsequent activation of effector caspases
3, 6 and 7, which will execute apoptosis. The cellular FLICE-
inhibitory protein (c-FLIP), which is vastly homologous to caspase
8 but lacks enzymatic activity, can also associate with the DISC,
blocking activation of caspase 8 through competition for binding
sites. It has also been stated that c-FLIP may function as an
activator of caspase 8 under specific circumstances (Micheau et al,
2002; Boatright et al, 2004). In addition, the intrinsic apoptotic
pathway can be activated by caspase 8 through cleavage of the
BH3-only protein Bid that triggers perturbation of the mitochon-
dria by Bax and Bak and finally activation of caspase 9 and effector
caspases (Li et al, 1998). Numerous studies have demonstrated that
drug resistance in cancer cells including ovarian cancer cells, could
be prevented or overcome by combining rhTRAIL with che-
motherapeutics (Mahalingam et al, 2009). In a previous study, we
showed that cisplatin can sensitise ovarian cancer cells to
rhTRAIL-induced apoptosis in vitro as well as in a bioluminescent
ovarian cancer xenograft model (Duiker et al, 2009). The described
mechanisms involved in modulation in ovarian cancer cells were
established by comparison of cell lines with different background Revised 7 January 2011; accepted 21 February 2011
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sand sensitivity patterns, which impede establishment of causal
relationships. Therefore, we investigated in an isogenic model of
cisplatin resistance the molecular determinants for rhTRAIL
sensitivity, the mechanism of synergy between cisplatin and
rhTRAIL and the role of functional p53 in this synergy.
MATERIALS AND METHODS
Cell lines
The ovarian cancer cell lines A2780 and its five-fold cisplatin-
resistant subline CP70, which carry wild-type and functional p53,
were a kind gift from Dr Hamilton (Fox Chase Cancer Center,
Philadelphia, PA, USA) (Godwin et al, 1992). Cisplatin resistance
in CP70 can partly be explained by an increased DNA repair
mechanism and a higher intracellular glutathione content
(Johnson et al, 1994). Cells grew as monolayers in RPMI 1640
(Life Technologies Breda, the Netherlands), supplemented with
10% heat-inactivated fetal calf serum (FCS) (Bodinco BV, Alkmaar,
the Netherlands) and 0.1 ML -glutamine. Cell lines were cultured in
a humidified atmosphere with 5% CO2.
Cytotoxicity assay
The microculture tetrazolium assay was used to measure
cytotoxicity as described earlier (Duiker et al, 2009). Treatment
consisted of continuous incubation with cisplatin (Pharmaco-
chemie BV, Haarlem, the Netherlands) or rhTRAIL (produced as
described earlier (Ashkenazi et al, 1999)) for 96h. The mean
IC50±s.d. was determined in three experiments, each performed in
quadruplicate.
Determination of apoptosis
In 96-well plates, cells were incubated with either rhTRAIL or
cisplatin, or both. The cells were exposed to cisplatin for 4h,
washed with phosphate-buffered saline (PBS: 6.4mM Na2HPO4;
1.5mM KH2PO4; 0.14mM NaCl; 2.7mM KCl; pH¼7.2) twice and
incubated in regular culture medium. At 20h after administration
of cisplatin, rhTRAIL was added for 4h. Following rhTRAIL
treatment, nuclear chromatin was stained with acridine orange to
identify apoptosis by fluorescence microscopy.
SDS–polyacrylamide gel electrophoresis and western
blotting
Cells were treated with rhTRAIL and/or cisplatin as described above.
Treatment with the proteasome inhibitor MG132 (Calbiochem, Breda,
the Netherlands) (0.5mM)l a s t e df o r2 4ha n dr h T R A I Lw a sa d d e df o r
the last 4h. The caspase inhibitor I (zVAD) (Calbiochem) was added
2h before MG132. Cycloheximide (CHX) (Sigma-Aldrich, Zwijndrecht,
the Netherlands) exposure was performed as indicated. After treatment,
t o t a lc e l ll y s a t e sw e r eg e n e r a t e da n dwestern blotting was performed as
described previously (Duiker et al, 2009), using the following primary
antibodies: Fas-associated death domain and XIAP (Transduction
Laboratories, Alphen a/d Rijn, the Netherlands), Bax, Bak, Bcl-2,
Bcl-XS/L and p53-DO-1 (Santa Cruz, Heerhugowaard, the Netherlands),
caspase 9 and Cip1/Waf1 (p21) (BD Biosciences, Alphen a/d Rijn, the
Netherlands), caspase 8 and cleaved caspase 3 (Cell Signaling, Leusden,
the Netherlands). The Bid- and FLIP NF6 antibodies were kindly
provided by Dr J Borst (The Netherlands Cancer Institute, Amsterdam,
the Netherlands) and Dr ME Peter (The Ben May Institute for Cancer
Research, Chicago, IL, USA), respectively. Secondary antibodies
conjugated with horseradish pero x i d a s ew e r eo b t a i n e df r o mD A K O
(Glostrup, Denmark). Equal protein loading was confirmed by b-actin
(ICN Pharmaceuticals, Zoetermeer, the Netherlands). Visualisation was
performed with BM Chemiluminescence Blotting Substrate (POD) or
LumiLight Plus Western Blotting Substrate (Roche Diagnostics,
Almere, the Netherlands).
Flow cytometry
Cells were collected using trypsin and washed once with cold PBS.
Cells were subsequently washed twice with cold PBS containing 2%
FCS and 0.1% sodium azide and incubated with phycoerythrin (PE)-
conjugated mouse monoclonal antibodies against DR4, DR5, decoy
receptor 1 (DcR1) and decoy receptor 2 (DcR2). Mouse PE-labelled
IgG1 and IgG2B were used as isotype controls. All PE-labeled
antibodies were purchased from R&D Systems (Oxon, UK).
Receptor membrane expression was analysed using a flow cytometer
(Epics Elite, Coulter Electronics, Hialeah, FL, USA) and is shown as
mean fluorescent intensity (MFI) of all analysed cells.
RNA interference and gene transfection
Small-interfering RNAs (siRNAs) were synthesised by Eurogentec
(Seraing, Belgium). The double-stranded c-FLIP siRNA was 50-GA
GGUAAGCUGUCUGUCGG-dTdT-30 (sense) and 50-CCGACAGAC
AGCUUACCUC-dTdT-30 (antisense). P53 siRNA 50-GCAUGAAC
CGGAGGCCCAU-dTdT-30 (sense) and 50-AUGGGCCUCCGGUUC
AUGC-dTdT-30 (anti-sense) was designed according to Martinez
et al (2002). Oligonucleotides specific for luciferase mRNA served
as a negative control (Elbashir et al, 2001). Caspase 8 siRNA
50-CUACCAGAAAGGUAUACCU-dTdT-30 (sense) and 50-AGGU
AUACCUUUCUGGUAG-dTdT-30 (anti-sense) was designed
according to Chun et al (2002) and negative control siRNA from
Eurogentec was used. Subconfluent cells were incubated in
unsupplemented Optimem medium and transfected with siRNA (up
to 133nM) using Oligofectamine reagent according to the manufac-
turer’s protocol (Invitrogen, Breda, the Netherlands). For the caspase
8 overexpression experiments, cells were transfected with pcDNA3-
FLICE (a gift from J Borst) using Fugene. The next day, cells were
treated with cisplatin and/or rhTRAIL as described above, collected
and used for protein isolation, cytospins, FACS experiments and/or
an apoptosis assay. Cytospins were immunohistochemically stained
for caspase 8 as described earlier (Duiker et al, 2010).
Real-time RT–PCR
Total RNA was isolated by guanidine isothiocyanate–phenol–
chloroform extraction with TRIzol (Invitrogen) and purified using
the RNeasy mini Kit and on-column DNase I digestion (Qiagen,
Leusden, the Netherlands) according to the manufacturer’s
instructions. Complementary DNA was synthesised from 1600ng
purified RNA as described by the manufacturer’s protocol (Life
Technologies) using oligo (dT)11 primers and MMLV transcrip-
tase. Real-time RT–PCR was performed in 96-wells plates on a
MyiQ real-time detection system (Bio-Rad, Veenendaal, the
Netherlands) with GAPDH as a housekeeping reference gene.
Primer sequences of caspase 8 were 50-GGAGCTGCTCTTCCGA
ATTA-30 (forward) and 50-GCAGGTTCATGTCATCATCC-30 (reverse)
and those of GAPDH were 50-CACCACCATGGAGAAGGCTGG-30
(forward) and 50-CCAAAGTTGTCATGGATGACC-30 (reverse).
Amplification of the samples in triplicate was carried out in a
final reaction volume of 25ml, containing 1  iQ SYBR Green
Supermix (Bio-Rad), 5mM of each primer and 5ml cDNA (1:50).
The thermocycling programme used for each real-time RT–PCR
consisted of an initial 3-min denaturation at 951C, followed by 40
cycles of 15-s denaturation at 951C, 20s primer annealing at the
primer specific Tann and 30-s fragment elongation at 721C. A
melting curve was obtained at the end of each 40 cycles of
amplification to determine the presence of a unique reaction
product. To determine RT–PCR efficiency and initial starting
quantity of the samples, a standard curve was generated using
samples from a 1:3 dilution series of total starting cDNA.
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sStatistical analysis
All experiments were performed at least three times on different
occasions. Analysis included double-sided non-paired Student’s
t-test. A P-value o0.05 was considered significant.
RESULTS
Combination of cisplatin and rhTRAIL causes enhanced
induction of apoptosis
A2780 was moderately sensitive to cisplatin treatment for 96h,
with an IC50 of 2.6mM in a survival assay. The subline CP70 was
five-fold resistant to cisplatin, with an IC50 of 14.7mM (Figure 1A).
The subline CP70 was rhTRAIL resistant, and A2780 was
moderately sensitive, as IC50 was not reached using up to
0.25mgml
 1 in a survival assay for 96h (Figure 1B). On the basis
of previous data, cells were treated for 4h with cisplatin, recovered
for 20h and treated with rhTRAIL for 4h for the apoptosis assay
(Duiker et al, 2009). Recombinant human TRAIL (0.25mgml
 1)
induced moderate levels of apoptosis in A2780, B20%, whereas
CP70 was not sensitive to rhTRAIL. Combination of cisplatin with
rhTRAIL enhanced apoptosis in both cell lines, with B80%
apoptosis in A2780 and B40% apoptosis in CP70 (Figure 1C).
The resistant cell line CP70 has reduced caspase 8 protein
levels
To determine which cellular characteristics could account for the
different sensitivity patterns to rhTRAIL, key components of the
TRAIL signalling pathway were analysed. Membrane expression of
DR4 and DcR1 were almost undetectable in both cell lines. Decoy
receptor 2 expression was similar, whereas DR5 was increased in
CP70 (MFI¼120±31) vs A2780 (MFI¼53±26) (Figure 2A).
Western blot analysis showed similar expression of FADD,
c-FLIPL, c-FLIPs, caspases 9 and 3, Bid, Bax, Bak, Bcl-2 and
Bcl-XL XIAP levels in A2780 and CP70. Remarkably, caspase
8 levels were lower in CP70 than in A2780 (Figure 2B).
Cisplatin induces upregulation of caspase 8 protein
Next, we evaluated the effect of cisplatin on TRAIL-receptor
expression and the effect of different regimens on cleavage of
caspases 8 and 9. Cisplatin did not affect DR4 and DcR1 levels.
Decoy receptor 2 was moderately upregulated, but DR5 was
strongly induced upon exposure to cisplatin in both cell lines
(Figure 2C). In response to cisplatin, moderate activation of
caspase 8 was induced in A2780. Recombinant human TRAIL
alone induced mild activation of caspases 8 and 9, whereas upon
combination treatment, both caspases were strongly activated. In
CP70, cisplatin induced upregulation of procaspase 8 levels.
Recombinant human TRAIL induced a slight activation of caspases
8 and 9, whereas the combination of cisplatin and rhTRAIL
resulted in strong activation of both caspases (Figure 2D).
Caspase 8 protein levels affect rhTRAIL-induced apoptosis
As caspase 8 protein levels are reduced in CP70 compared with
A2780, we examined the importance of caspase 8 protein levels
for rhTRAIL-sensitivity following cisplatin pre-treatment.
Efficient downregulation of caspase 8 with siRNA strongly reduced
apoptosis induction following treatment of A2780 and CP70
with rhTRAIL alone and combined with cisplatin (Figure 3A).
In caspase 8 siRNA-transfected cells, combined treatment
with cisplatin and rhTRAIL minimally induced caspases 8 and 3
activation, whereas in negative control siRNA-transfected cells,
strong activation of both caspase 8 and 3 was observed (Figure 3B).
It can be noticed that caspase 3 levels are also slightly upregulated
following cisplatin in both cell lines (Figure 3B). A role for caspase
3 in rhTRAIL sensitisation can therefore not be excluded.
However, the importance of caspase 8 levels was also demonstrated
by transient upregulation of caspase 8 in CP70 that enhanced
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Figure 1 Resistance to cisplatin causes cross-resistance to rhTRAIL. Combination therapy overcomes resistance. (A) Survival after 96h exposure to
0–25mM ( A 2 7 8 0 )o r0–1 0 0mM (CP70) cisplatin and (B) survival after 96h exposure to 0mgml
 1–0.25mgml
 1 rhTRAIL as measured by cytotoxicity assays. (C)
To determine apoptosis induction, cells were treated for 4h with cisplatin (2.5, 10 and 30mM) after which cisplatin was washed away. Twenty hours later, the cells
were treated for 4h with 0.25mgml
 1 rhTRAIL. Apoptosis was determined with acridine orange staining. Apoptosis in the combinations marked with * was
significantly enhanced (Po0.05) over apoptosis after single-agent treatment. Data represent the mean±s.d. of at least three independent experiments.
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sapoptosis induction by rhTRAIL alone and by the rhTRAIL–
cisplatin combination (Figures 3C and D).
Cisplatin increases caspase 8 mRNA levels
We investigated the mechanism causing reduced basal caspase 8
protein levels and cisplatin-induced caspase 8 upregulation in
CP70. Basal caspase 8 mRNA levels were slightly higher in CP70
than in A2780. Exposure to cisplatin resulted in 1.5-fold induction
of caspase 8 mRNA in both the cell lines (Figure 4A). Possible
differences in mRNA stability over time and in response to
cisplatin were determined using actinomycin D. Caspase 8 mRNA
degradation in the absence or presence of cisplatin was not
different between A2780 and CP70 (P¼0.35) (Figure 4B). These
results show that cisplatin does not influence caspase 8 mRNA
degradation, indicating that the induction of mRNA is caused by
increased transcription.
Caspase 8 protein translation is reduced in CP70
The similar caspase 8 mRNA expression, whereas different basal
caspase 8 protein levels were observed, suggest possible changes in
caspase 8 protein translation or degradation in CP70. Cells were
exposed to the proteasome inhibitor MG132 to test whether
increased proteasomal degradation causes the reduced caspase 8
protein levels in CP70. Treatment with MG312 induced upregula-
tion of active caspase 8, leading to concomitant synergy with
rhTRAIL (Figure 4C). To prevent caspase 8 activation by MG132
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Figure 2 Cellular characteristics involved in sensitivity to rhTRAIL. Cisplatin can induce caspase 8 protein in the low caspase 8-expressing CP70. (A) Basic levels of
TRAIL receptor membrane expression in A2780 and CP70 as determined by FACS analysis. Receptor expression is expressed as MFI. (B) Western blot analysis of
basic protein expression levels of key determinants of the TRAIL pathway in A2780 and CP70. (C) The effect of cisplatin on DR5 expression in both cell lines. Flow
cytometry was performed at 24h after 4h incubation with cisplatin. (D) Western blot analysis of caspases 8 and 9 after exposure to cisplatin and rhTRAIL. A2780
and CP70 were incubated with 2.5mM or 30mM cisplatin during 4h, after which the cells were washed. Twenty hours later, unexposed or cisplatin-exposed cells were
treated during 4h with 0.25mgml
 1 rhTRAIL. b-Actin serves as a loading control. The blots are representative for at least three independent experiments.
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streatment, cells were co-incubated with the caspase inhibitor
zVAD for 24h, which did not lead to a change in full-length
caspase 8 levels (Figure 4D). Cycloheximide exposure for up to
24h slightly affected caspase 8 levels in both cell lines, whereas
caspase 8 degradation was not different between A2780 and CP70
(Figure 4E). These results show that not caspase 8 protein stability
but rather a decreased translation of caspase 8 mRNA is causing
the reduced caspase 8 expression in CP70.
Increased caspase 8 but not the caspase 8/c-FLIP ratio is
involved in the response to cisplatin and rhTRAIL in CP70
Difference in caspase 8/c-FLIP ratio between A2780 and CP70
might contribute to resistance in CP70. However, efficient down-
regulation of both c-FLIPL and c-FLIPs with siRNA did not lead to
increased apoptosis after either treatment regimen, and did not
affect caspase 8 cleavage (Figure 5A). Downregulation even led to a
significant decrease in apoptosis in CP70 (Figure 5B). These results
indicate that solely the elevated caspase 8 level is involved in the
onset of apoptosis after combination treatment in CP70. Moreover,
c-FLIP even promotes caspase 8 activation in these cells.
P53 causes cisplatin-induced DR5 expression, but is not
involved in rhTRAIL sensitisation
As p53-induced upregulation of DR5 is frequently described to be
instrumental in the synergistic effect between chemotherapeutics
and rhTRAIL (Wu et al, 2004), we asked whether the synergistic
effect of cisplatin and rhTRAIL was p53 dependent. The tumor
suppressor protein p53 was efficiently and functionally down-
regulated using siRNA in A2780 and CP70 as shown by the
decreased expression of p21 (Waf1/Cip1), a transcriptional target
of p53 (Figure 6A). In response to cisplatin, p53 levels rose slightly
in p53-suppressed cells, but the levels remained far below those in
the untreated luciferase siRNA-transfected cells. Apoptosis induc-
tion (Figure 6B) and activation of caspases 8, 9 and 3 (Figure 6C)
were not affected by p53 siRNA. Following p53 downregulation,
basal DR5 membrane expression maintained unchanged, whereas
+
CP70 A2780
+
+
–
–
+
–
–
+
+
+
–
–
+
–
–
–
–
+
+
+
–
–
+
–
–
+
+
+
–
–
+
–
–
–
–
CP70 A2780
rhTRAIL
0.25g ml–1
A2780
0
20
40
60
80
0
Cisplatin (M)
A
p
o
p
t
o
s
i
s
 
(
%
)
CP70
0
20
40
60
80
Neg c siRNA –rhTRAIL Neg c siRNA + rhTRAIL Casp 8 siRNA + rhTRAIL
0
10
20
30
40
50 CP70 - rhTRAIL
CP70 + rhTRAIL
CP70 + casp 8 + rhTRAIL
A
p
o
p
t
o
s
i
s
 
(
%
)
Caspase 8
Caspase 3
Active caspase 3
-Actin
55kDa
43/41kDa
18kDa
32kDa
19/17kDa
42kDa
Neg contr siRNA Caspase 8 siRNA Neg contr siRNA Caspase 8 siRNA
Cisplatin 30M
30 20 10 0
Cisplatin (M)
30 20 10
0
Cisplatin (M)
30 20 10
Figure 3 Caspase 8 downregulation inhibits cisplatin and rhTRAIL-induced apoptosis, whereas caspase 8 upregulation augmented apoptosis induction.
A2780 and CP70 were transfected with siRNA against caspase 8 or negative control siRNA (A and B). The CP70 cells were transiently transfected with a
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scisplatin-induced DR5 membrane expression was effectively
suppressed in A2780 and CP70 (Figure 6D). These results show
that p53-dependent upregulation of DR5 is not involved in the
synergy between cisplatin and rhTRAIL. In addition, DISC-IP
using a DR5 antibody following cisplatin treatment showed that
DISC formation is not impeded in CP70 (data not shown).
DISCUSSION
In the present study, we show that the cellular caspase 8 protein
level is an important determinant of sensitivity to rhTRAIL-
induced apoptosis in an isogenic ovarian cancer cell line model of
acquired cisplatin resistance. Combination of cisplatin and
rhTRAIL effectively induced apoptosis, with cisplatin-induced
caspase 8 protein expression being the key factor of sensitisation to
rhTRAIL in CP70. The central role of caspase 8 was further
indicated by our observation that cisplatin-induced DR5
upregulation was not an important sensitising factor. As caspase
8 mRNA levels do not differ significantly between A2780 and
CP70, the low caspase 8 protein levels in CP70 are likely to be
caused by decreased translation of caspase 8 protein rather than
decreased transcription through methylation or genetic alterations
that occur in neuroblastoma (Teitz et al, 2000; Takita et al, 2001)
and in other solid tumours (Kim et al, 2003; Soung et al, 2005).
Increased caspase 8 protein degradation in CP70 was ruled out, as
the effect of inhibition of protein synthesis and proteasomal
degradation on caspase 8 levels was not different between A2780
and CP70.
Translational and post-translational modifications are impor-
tant factors of the expression levels and activity of key proteins
in the regulation of cell survival and apoptosis such as p53
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Figure 4 Stability of caspase 8 mRNA or protein does not differ between A2780 and CP70. Differences in caspase 8 protein levels in CP70 are due to
changes in protein translation. (A) Expression of caspase 8 mRNA was determined with quantitative RT–PCR after exposure to 30mM cisplatin,
0.25mgml
 1 rhTRAIL or the combination in both cell lines. Cells were incubated for 4h with cisplatin, after which the cells were washed and total RNA was
isolated 20h after cisplatin exposure. Total RNA was isolated 4h after exposure to rhTRAIL. Quantitative RT–PCR was carried out on cDNA with the
SYBR Green method. Quantification was performed with the standard curve method with GAPDH as reference. Basic mRNA levels between A2780 and
CP70 were not different. Cisplatin induced caspase 8 mRNA by 1.5 fold. (B) To assess caspase 8 mRNA stability, cells were exposed to 30mM cisplatin for
4h or left untreated. Hereafter, all conditions were washed with PBS and received new medium, followed by addition of 5mgml
 1 actinomycin D (Act D).
Total RNA was extracted at the time of Act D addition (t¼0h) and at the indicated time points. Quantitative RT–PCR was performed as in (A). Data
represent the mean±s.d. of at least three independent experiments. (C) A2780 and CP70 were exposed to 0.5mM of the proteasome inhibitor MG132 for
24h. The following day either rhTRAIL was added the last 4h of incubation, or the cells were left untreated. Then cells were lysed and subjected to western
blot analysis with caspase 8 and 3 antibodies. (D and E) The A2780 and CP70 cell lines were treated with 0.5mM MG132 for the indicated time points in the
presence of 50mM of z-VAD and lysed or treated with 20mgml
 1 cycloheximide (CHX) for the indicated time points and lysed. Following SDS–PAGE,
immunoblotting was carried out with caspase 8 antibodies. b-Actin serves as a loading control. All immunoblots are representative for at least three
independent experiments.
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s(Xu, 2003), p73 (Ozaki et al, 2005), XIAP and APAF-1 (Holcik and
Sonenberg, 2005). Recently, attention has been drawn to micro-
RNAs (miRNAs) as important regulators of translation and mRNA
stability (Kent and Mendell, 2006). Deregulation of several
miRNAs was described for ovarian cancer, and an important role
for miRNAs in cisplatin and TRAIL resistance was shown in
ovarian and lung cancer, respectively (Garofalo et al, 2008;
Yang et al, 2008). In melanoma cells, an inducible post-
translational modification of mRNA contributed to TRAIL
resistance, in which cytosolic proteins could suppress DR5 protein
expression by binding to the 30-untranslated region of DR5-mRNA
(Zhang et al, 2004). These studies support our hypothesis that a
post-transcriptional mechanism is involved in the low expression
of caspase 8 in CP70. The fact that most prominently in CP70,
caspase 8 translation could be enhanced by cisplatin exposure
argues in favour of a reversible block of translation. Low caspase
8 levels were previously shown to contribute to rhTRAIL resistance
in several cell line models and tumours (Hopkins-Donaldson
et al, 2000; Zhang et al, 2005). Regarding the role of caspase 8
and the extrinsic apoptotic pathway in chemotherapy-induced cell
death, conflicting reports have been published. Death receptor-
dependent and -independent activation of caspase 8 was involved
in the response to different chemotherapeutic drugs (Fulda et al,
2001; Spierings et al, 2003; Longley et al, 2006). In addition,
resistance to these drugs through defects in the extrinsic pathway
further supported the involvement of this pathway in chemother-
apy-induced cell death (Abedini et al, 2004; Longley et al, 2006).
Besides the differential expression of caspase 8, we found no
other proteins that could account for the difference in rhTRAIL
sensitivity between A2780 and CP70. As caspase 3 was slightly
upregulated in both cell lines following cisplatin, a role for caspase
3 and hence also for XIAP can not be completely ruled out (Fraser
et al, 2003). However, basal caspase 3 levels did not differ between
the two cell lines, excluding caspase 3 as a determinant for the
difference in rhTRAIL sensitivity. A reduced caspase 8/c-FLIP
ratio can result in resistance to DR signalling (Mitsiades et al,
2002; Baumler et al, 2003), whereas an increased caspase 8/c-FLIP
ratio in the DISC can cause sensitisation to rhTRAIL by
chemotherapeutics (Lacour et al, 2003; Ganten et al, 2004). In
our cell lines, downregulation of c-FLIP did not increase apoptosis
induction. In the resistant CP70, downregulation of c-FLIP even
resulted in a significant drop in apoptosis levels after exposure to
cisplatin and rhTRAIL. This suggests that c-FLIP functions as a
pro-apoptotic protein in CP70 and that the caspase 8 level is the
most important determinant for rhTRAIL sensitivity. Although
extensive literature exists on the anti-apoptotic function of c-FLIP,
a role of c-FLIP in activation of caspase 8 was also reported
(Micheau et al, 2002; Boatright et al, 2004). It is postulated that the
c-FLIPL concentration at the DISC determines whether caspase 8
activation or inhibition occurs (Boatright et al, 2004; Peter, 2004).
Thus, it can be reasoned that the caspase 8-activating function of
FLIP applies to A2780 and CP70, especially when low caspase 8
levels are present and heterodimerisation can occur more easily
than homodimerisation.
Upregulation of DR4 or DR5, which can occur in a p53-
dependent or -independent manner in response to chemother-
apeutics (Wu et al, 1997; Sheikh et al, 1998), is often described as a
key event in the synergistic effect between chemotherapeutics and
rhTRAIL (Wu et al, 2004). In this study, we show that the increase
of DRs after chemotherapy treatment might just be an epipheno-
menon, instead of a key event in modulation of rhTRAIL-induced
cell death by chemotherapeutics. Downregulation of p53 did not
affect apoptosis induction in both cell lines, whereas the
substantial increase of DR5 after treatment with cisplatin was
almost completely abrogated by p53 downregulation. It has been
shown that p53 is required for cisplatin-induced apoptosis either
via p53-dependent ubiquitination of FLIP or through p53-induced
XIAP and Akt downregulation when used as a single agent (Fraser
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Figure 5 The caspase 8/c-FLIP ratio is not involved in resistance to rhTRAIL. Cells were transfected with siRNA against c-FLIP or luciferase. The next day,
cells were exposed to cisplatin for 4h, after which all cells including those conditions left unexposed were washed. The following day after 4h incubation
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 1 rhTRAIL cell lysates were made (A) Cellular FLICE-inhibitory protein (c-FLIP) and caspase 8 cleavage was determined with
western blot analysis. The exposure time of the caspase 8 blot of CP70 was increased compared with the blot of A2780. The blots are representative for at
least three independent experiments. (B) A small fraction of the same cell suspension used for western blot was plated in a 96-wells plate and apoptosis
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set al, 2003; Abedini et al, 2008). These results may explain why CP70
has reduced caspase 8 levels compared with A2780. However, in our
experiments we have chosen to use cisplatin in a short-treatment
setting. This was followed by a short treatment with rhTRAIL, and we
have demonstrated that upon combination of cisplatin and rhTRAIL,
p53 is no longer required for apoptosis induction.
Conclusively, these results show that cisplatin enhances
rhTRAIL sensitivity in both cisplatin-sensitive and -resistant cells.
Induction of caspase 8 protein expression is the key factor of
rhTRAIL sensitisation.
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